Evidence map›Paper›PMID 37723073›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Problems and pitfalls of the hepatocyte-specific contrast agent gadoxetate disodium for assessing the main criteria of LI-RADS version 2018].

R Guo, S C Zhu

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

R GuoDepartment of Radiology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China.
S C ZhuDepartment of Radiology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China.

Funding

Key Research and Promotion Projects in Henan Province (Scientific and Technological Research) 212102310729Zhengzhou Collaborative Innovation Major Project 20XTZX11020
6 · The paper itself

Abstract

Although main criteria like non-rim enhancement in the arterial phase, non-peripheral washout, enhancing envelope, lesion size, and threshold growth have definitions and interpretations in the Liver Imaging Reporting and Data System, there are still some problems and pitfalls that clinicians and radiologists need to understand and avoid when assessing the main criteria based on gadoxetate disodium in clinical work-up. This article reviews the existing problems and current solutions in the assessment of the main criteria based on the hepatic contrast agent gadoxetate disodium.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsContrast MediaGadolinium DTPAHepatocytesHumansContrast MediaGadolinium DTPAgadolinium ethoxybenzyl DTPAHepatocellular carcinomaHepatocyte-specific contrast mediumMagnetic resonance imaging

Identifiers

PMID37723073
PMCPMC12814646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.